JP2011520900A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011520900A5 JP2011520900A5 JP2011509662A JP2011509662A JP2011520900A5 JP 2011520900 A5 JP2011520900 A5 JP 2011520900A5 JP 2011509662 A JP2011509662 A JP 2011509662A JP 2011509662 A JP2011509662 A JP 2011509662A JP 2011520900 A5 JP2011520900 A5 JP 2011520900A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- epilepsy
- episode
- psd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 claims 17
- 229940124597 therapeutic agent Drugs 0.000 claims 17
- 206010015037 epilepsy Diseases 0.000 claims 11
- 206010010904 Convulsion Diseases 0.000 claims 3
- 102100022264 Disks large homolog 4 Human genes 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 108700019745 Disks Large Homolog 4 Proteins 0.000 claims 2
- 102000000470 PDZ domains Human genes 0.000 claims 2
- 108050008994 PDZ domains Proteins 0.000 claims 2
- 229940123119 PSD-95 Inhibitor Drugs 0.000 claims 1
- 108010046423 Tat-NR2B9c Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- XWQVQFBTSBCKLI-FKXNDIMNSA-N dnc008987 Chemical group CC(C)[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC1=CC=C(O)C=C1 XWQVQFBTSBCKLI-FKXNDIMNSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000028329 epileptic seizure Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 230000002085 persistent effect Effects 0.000 claims 1
- 201000008914 temporal lobe epilepsy Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5410908P | 2008-05-16 | 2008-05-16 | |
| US61/054,109 | 2008-05-16 | ||
| PCT/US2009/043831 WO2009140416A2 (en) | 2008-05-16 | 2009-05-13 | Treatment for epilepsy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016109744A Division JP2016199553A (ja) | 2008-05-16 | 2016-06-01 | てんかんの治療 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011520900A JP2011520900A (ja) | 2011-07-21 |
| JP2011520900A5 true JP2011520900A5 (enExample) | 2012-06-14 |
| JP6005357B2 JP6005357B2 (ja) | 2016-10-12 |
Family
ID=41319319
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509662A Expired - Fee Related JP6005357B2 (ja) | 2008-05-16 | 2009-05-13 | てんかんの治療 |
| JP2016109744A Pending JP2016199553A (ja) | 2008-05-16 | 2016-06-01 | てんかんの治療 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016109744A Pending JP2016199553A (ja) | 2008-05-16 | 2016-06-01 | てんかんの治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9161965B2 (enExample) |
| EP (1) | EP2307035B1 (enExample) |
| JP (2) | JP6005357B2 (enExample) |
| CN (1) | CN102088990A (enExample) |
| AU (1) | AU2009246316B2 (enExample) |
| CA (1) | CA2724483C (enExample) |
| DK (1) | DK2307035T3 (enExample) |
| ES (1) | ES2446306T3 (enExample) |
| WO (1) | WO2009140416A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| WO2008112661A2 (en) | 2007-03-09 | 2008-09-18 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
| JP6005357B2 (ja) | 2008-05-16 | 2016-10-12 | ノノ インコーポレイテッド | てんかんの治療 |
| AU2009288088B2 (en) * | 2008-09-03 | 2014-12-04 | Nono Inc. | Agents and methods for treatment of pain |
| US20140323924A1 (en) * | 2013-04-26 | 2014-10-30 | David J. Mishelevich | Targeted optogenetic neuromodulation for treatment of clinical conditions |
| CN105072993B (zh) | 2013-01-31 | 2020-04-14 | 加利福尼亚大学董事会 | 正常和疾病状态脑动力学的建模系统和方法 |
| JP6884703B2 (ja) | 2015-02-25 | 2021-06-09 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニアＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃａｌｉｆｏｒｎｉａ | 障害を治療するための５ｈｔ作動薬 |
| WO2017093354A1 (en) | 2015-11-30 | 2017-06-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nmdar antagonists for the treatment of diseases associated with angiogenesis |
| ES2869300T3 (es) * | 2016-04-27 | 2021-10-25 | Biocells Beijing Biotech Co Ltd | Péptido terapéutico para las lesiones relacionadas con la neurotoxicidad excitadora |
| KR20180135493A (ko) * | 2016-04-27 | 2018-12-20 | 바이오셀즈(베이징) 바이오테크 코., 엘티디. | 흥분성 신경독성 관련 손상의 치료 방법 |
| KR102871666B1 (ko) | 2016-12-09 | 2025-10-15 | 알렉스자 파마스티칼즈, 인크. | 간질 치료 방법 |
| EA039314B1 (ru) * | 2017-07-05 | 2022-01-12 | Биоселз (Бейдзин) Биотек Ко., Лтд. | Фармацевтически приемлемые соли полипептидов и их применение |
| WO2019061395A1 (zh) | 2017-09-30 | 2019-04-04 | 拜西欧斯（北京）生物技术有限公司 | 兴奋性神经毒性相关损伤的治疗肽组合物 |
| CA3085576A1 (en) | 2017-12-13 | 2019-06-20 | The Research Foundation For The State University Of New York | Peptides and other agents for treating pain and increasing pain sensitivity |
| EP3746138B1 (en) | 2018-02-02 | 2025-12-10 | Alexza Pharmaceuticals, Inc. | Electrical condensation aerosol device |
| CN113164527A (zh) * | 2018-09-27 | 2021-07-23 | 芬奇治疗控股有限责任公司 | 用于治疗癫痫和相关障碍的组合物和方法 |
| EP4031114A1 (en) * | 2019-09-17 | 2022-07-27 | Zogenix International Limited | Methods of treating epileptic patients with fenfluramine |
| CN110627877A (zh) * | 2019-09-25 | 2019-12-31 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
| CN111285923B (zh) * | 2020-03-05 | 2023-02-03 | 成都奥达生物科技有限公司 | 一种psd-95抑制剂 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060148711A1 (en) * | 1999-05-14 | 2006-07-06 | Arbor Vita Corporation | Molecular interactions in neurons |
| US20050019841A1 (en) * | 1999-05-14 | 2005-01-27 | Arbor Vita Corporation | Modulation of signaling pathways |
| US7595297B2 (en) * | 1999-06-02 | 2009-09-29 | Michael Tymianski | Method of reducing injury to mammalian cells |
| US20050282743A1 (en) * | 2001-08-03 | 2005-12-22 | Arbor Vita Corporation | Molecular interactions in cells |
| US20090075377A1 (en) * | 2001-08-03 | 2009-03-19 | Arbor Vita Corporation | Molecular interactions in cells |
| US7858322B2 (en) * | 2003-12-23 | 2010-12-28 | Nono, Inc. | Method of determining inhibition of binding to TRPM7 protein |
| WO2005097090A2 (en) * | 2004-04-05 | 2005-10-20 | Icos Corporation | AGENTS THAT DISRUPT PSD95 - nNOS INTERACTION, COMPOSITIONS CONTAINING THE SAME, AND THERAPEUTIC USES THEREOF |
| WO2007002395A1 (en) * | 2005-06-23 | 2007-01-04 | Arbor Vita Corporation | Methods and compositions for modulating cox |
| US20070021501A1 (en) * | 2005-07-12 | 2007-01-25 | Twyman Roy E | Methods of treating epileptogenesis |
| US8633160B2 (en) * | 2005-12-30 | 2014-01-21 | Nono Inc. | Small molecule inhibitors of PDZ interactions |
| KR101384572B1 (ko) * | 2005-12-30 | 2014-04-24 | 아버 비타 코포레이션 | Ｐｄｚ 상호작용의 소형 분자 억제제 |
| EP1884521A1 (en) * | 2006-07-31 | 2008-02-06 | Xigen S.A. | Fusion peptide for inhibiting interaction of neuronal NMDA receptor (NMDAR) and NMDAR interacting proteins |
| EP2120987B1 (en) * | 2007-03-02 | 2014-01-15 | NoNO Inc. | Treating stroke and other diseases without inhibiting n-type calcium channels |
| US8008253B2 (en) * | 2007-07-03 | 2011-08-30 | Andrew Tasker | Treatment for anxiety |
| US8080518B2 (en) * | 2007-12-05 | 2011-12-20 | Arbor Vita Corporation | Co-administration of an agent linked to an internalization peptide with an anti-inflammatory |
| JP6005357B2 (ja) | 2008-05-16 | 2016-10-12 | ノノ インコーポレイテッド | てんかんの治療 |
| AU2009288088B2 (en) * | 2008-09-03 | 2014-12-04 | Nono Inc. | Agents and methods for treatment of pain |
-
2009
- 2009-05-13 JP JP2011509662A patent/JP6005357B2/ja not_active Expired - Fee Related
- 2009-05-13 EP EP09747499.3A patent/EP2307035B1/en active Active
- 2009-05-13 ES ES09747499.3T patent/ES2446306T3/es active Active
- 2009-05-13 AU AU2009246316A patent/AU2009246316B2/en not_active Ceased
- 2009-05-13 DK DK09747499.3T patent/DK2307035T3/da active
- 2009-05-13 WO PCT/US2009/043831 patent/WO2009140416A2/en not_active Ceased
- 2009-05-13 CN CN2009801274025A patent/CN102088990A/zh active Pending
- 2009-05-13 CA CA2724483A patent/CA2724483C/en active Active
- 2009-05-14 US US12/466,208 patent/US9161965B2/en active Active
-
2016
- 2016-06-01 JP JP2016109744A patent/JP2016199553A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011520900A5 (enExample) | ||
| WO2008011174A3 (en) | Jak inhibitors for treatment of myeloproliferative disorders | |
| WO2007025613A3 (en) | Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain | |
| TWI371276B (en) | Use of brimonidine for manufacture of a medicament for preventing or reducing severity of sensory hypersensitivity associated with migratine | |
| MX2009012163A (es) | Hetarilanilinas como moduladores para beta-amiloide. | |
| IL201479A (en) | Use of tapentadol for the preparation of pain medication | |
| WO2011011186A3 (en) | Hdac inhibitors and therapeutic methods using the same | |
| IL219857A0 (en) | Mitotic kinesin inhibitors, pharmaceutical compositions comprising them, uses thereof in the manufacture of a medicament for the treatment of disease or disorder in a human or animal that can be treated by inhibiting mitosis | |
| NZ715686A (en) | Pharmaceutical for oral delivery comprising mgbg and methods of treating disease | |
| MX2009012188A (es) | Métodos de tratamiento y prevención de enfermedades y desórdenes neurodegenerativos. | |
| WO2009140416A3 (en) | Treatment for epilepsy | |
| WO2007138466A3 (en) | Pharmaceutical compositions comprising meloxicam and tramadol combination | |
| MX2012003324A (es) | Compuesto de glicina. | |
| TR201814245T4 (en) | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS. | |
| JP2016501219A5 (enExample) | ||
| WO2015079010A3 (en) | Pharmaceutical composition comprising lacosamide and levetiracetam | |
| WO2005089515A3 (en) | Methods for the treatment of synucleinopathies | |
| EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
| WO2008073466A3 (en) | Alpha b-crystallin as a therapy for inflammation | |
| JP2009178162A5 (enExample) | ||
| WO2012138879A3 (en) | Peptides for the treatment of hearing | |
| MX366496B (es) | Metodos para preparar composiciones farmaceuticas que comprenden acetato de eslicarbazepina y metodos de uso. | |
| MX2014014814A (es) | Composicion farmaceutica para el tratamiento de inflamacion y dolor. | |
| TW201129361A (en) | Methods for treating pain | |
| HK1202420A1 (en) | Methods for treating psoriasis and vascular inflammation |